Wainua: Dosage Form, Projected Sales, NCE-1 Date | Eplontersen

Wainua

Wainua is a subcutaneous injection designed for adults managing nerve damage caused by hereditary transthyretin-mediated amyloidosis (ATTRv‑PN). It works via an antisense therapy that reduces the abnormal protein buildup damaging the nerves.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Eplontersen
Innovator :

ASTRAZENECA AB
Approval Date :

21-Dec-23
NCE-1 Date :

21-Dec-27
NCE Date :

21-Dec-28
Dosage Form :

Subcutaneous Injection
Strength :

45MG BASE/0.8ML
Therapeutic Category :

Neuroprotective
Revenue ($M) :

105

Year-wise Projected Sales ($M) :

2025 :

305
2026 :

535
2027 :

938
2028 :

1,358
2029 :

1,855
2030 :

2,302
2031 :

2,746

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Wainua

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?